CKB News Archive



  • 2022
    • July
      • Time for the next quarterly update to the CORE gene list! We are highlighting the tyrosine kinase genes this quarter. If you have any questions/comments, please feel free to reach out to us at ckbsupport@jax.org!
  • 2022
    • April
      • Did you know you can find content related to TMB (tumor mutational burden), MSI (microsatellite instability), TILs (tumor infiltrating lymphocytes), and HRD (homologous repair deficiency) in CKB BOOST? Each biomarker can be found using 'Explore by Gene' or 'Explore by Variant'! Have questions or comments? Feel free to e-mail us at ckbsupport@jax.org.
  • 2022
    • March
      • CKB BOOST update! You can now find clinical trials for select countries other than the US and Canada. The list currently includes France, Germany, Spain, Italy, Austria, and Belgium. Have questions or comments on how to best search for clinical trials? Email us at ckbsupport@jax.org!
  • 2022
    • February
      • NEW FEATURES in CKB BOOST! Want to quickly assess whether your variant is a polymorphism or results in transforming activity? Check out the Gene Variant Detail pages, which now include indicators for Polymorphism and Transforming Activity! Questions or comments? Contact us at ckbsupport@jax.org.
  • 2022
    • January
      • It's time for the next quarterly update to the CKB CORE gene list! This quarter we are highlighting genes relevant to immuno-oncology. For more information about the genes available, check out the latest CKB CORE quarterly newsletter here. Have questions or comments? Email us at ckbsupport@jax.org
  • 2020
    • October
      • Exciting news! CKB CORE and BOOST now include clinical trial locations and contact details! Need more information or have questions? Email us at ckbsupport@jax.org.
  • 2020
    • September
      • CKB UPDATE! CORE and BOOST now include transcripts with version numbers. Questions? Feel free to contact us at ckbsupport@jax.org.
  • 2020
    • July
      • New FDA approval for Atezolizumab plus Cobimetinib and Vemurafenib for patients with BRAF V600-positive advanced melanoma! Find more information on this in CKB CORE. Need up-to-date information on other FDA drug approvals? Consider a CKB BOOST subscription, which includes full access to all drugs and their FDA approvals, along with related content!
  • 2020
    • January
      • CKB CORE now offers content for RSPO3, POLE, FANCA, and DOT1L, but removes EGFR, PTEN, TP53, and MET. However, these genes are always accessible with a CKB BOOST subscription!
  • 2019
    • October
      • Have a question about CKB or want to learn more about it? Then check out The Scoop on CKB!
  • 2019
    • July
      • CKB BOOST now has AMP/CAP/ASCO evidence level coding!
  • 2018
    • November
      • Vitrakvi (larotrectinib) approved regardless of tumor type for NTRK fusions, except with acquired resistance mutations! Need a list of resistance mutations? Visit ckbhome.jax.org and sign-up for CKB BOOST.
  • 2017
    • October
      • Barriers preventing the adoption of comprehensive cancer genomic profiling in the clinic (PMID: 28402162). Limited free copies available; request your copy at ckbsupport@jax.org.